Wang Jian, Ye Ling, Cai Hui, Jin Meiling
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200030, China.
J Cancer. 2019 Jul 10;10(18):4226-4236. doi: 10.7150/jca.33367. eCollection 2019.
: In 2015, large cell neuroendocrine carcinoma (LCNEC) was removed from the large cell carcinoma group and classified with small cell lung carcinoma (SCLC) constituting two members of the high-grade neuroendocrine tumors (NETs) of the lung. However, the difference between high-grade LCNEC and SCLC in terms of clinicopathological characteristics and prognosis has not been fully understood owing to the rarity of LCNEC. : Patients with high-grade LCNEC and SCLC at initial diagnosis between 2001 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) program database. Clinicopathological characteristics between high-grade LCNEC and SCLC were compared using the Pearson's chi-squared test or Fisher's exact test. Differences in overall survival (OS) and cancer-specific survival (CSS) were compared using the log-rank test, Cox models and propensity score matching (PSM) analysis. : A total of 1223 patients with high-grade LCNEC and 18182 patients with high-grade SCLC were enrolled. To the best of our knowledge, this study involved the largest number of high-grade LCNEC patients to date, with respect to a comparison between high-grade LCNEC and high-grade SCLC patients. There were significant differences in age, sex, race, laterality, SEER stage, nodal status, surgery, radiation and chemotherapy, but not marital status, between high-grade LCNEC and SCLC patients. High-grade LCNEC patients had a better OS and CSS than high-grade SCLC patients. Subgroup analysis also confirmed the better prognosis of the high-grade LCNEC patients in the regional stage, distant stage and surgery subgroups. However, no significant difference in prognosis was observed between the two non-surgery subgroups, which was confirmed using PSM analysis. Furthermore, high-grade LCNEC patients showed different metastatic patterns to high-grade SCLC patients. : These results suggested that high-grade LCNEC and high-grade SCLC were different histological types, and that a detailed classification for high-grade NETs of the lung was needed.
2015年,大细胞神经内分泌癌(LCNEC)从大细胞癌组中分离出来,并与小细胞肺癌(SCLC)归为一类,构成肺高级别神经内分泌肿瘤(NETs)的两个成员。然而,由于LCNEC罕见,高级别LCNEC与SCLC在临床病理特征和预后方面的差异尚未完全明确。利用监测、流行病学和最终结果(SEER)计划数据库确定2001年至2014年初次诊断为高级别LCNEC和SCLC的患者。使用Pearson卡方检验或Fisher精确检验比较高级别LCNEC与SCLC的临床病理特征。使用对数秩检验、Cox模型和倾向评分匹配(PSM)分析比较总生存期(OS)和癌症特异性生存期(CSS)的差异。共纳入1223例高级别LCNEC患者和18182例高级别SCLC患者。据我们所知,就高级别LCNEC与高级别SCLC患者的比较而言,本研究涉及到迄今为止数量最多的高级别LCNEC患者。高级别LCNEC与SCLC患者在年龄、性别、种族、肺叶、SEER分期、淋巴结状态、手术、放疗和化疗方面存在显著差异,但婚姻状况无差异。高级别LCNEC患者的OS和CSS优于高级别SCLC患者。亚组分析也证实了高级别LCNEC患者在区域分期、远处分期和手术亚组中的预后较好。然而,两个非手术亚组之间未观察到预后的显著差异,PSM分析证实了这一点。此外,高级别LCNEC患者与高级别SCLC患者的转移模式不同。这些结果表明,高级别LCNEC和高级别SCLC是不同的组织学类型,需要对肺高级别NETs进行详细分类。